ROARABLE
FREE $100K
My Trading Account →
▾
Trading Account Active
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / LTGO / dividends
OBX (36) KURA (31) JBIO (31) ORIC (30) ⌘ Pro Terminal →

Latigo Biotherapeutics Inc. (LTGO) Dividend Safety Gauge & 10-Year DRIP Compounder

$13.51 -3.15% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $13.41

Latigo Biotherapeutics Inc. (LTGO) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $924.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LTGO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LTGO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Latigo Biotherapeutics Inc. (NASDAQ: LTGO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $13.51 (-3.15% 1D, market cap $924.9M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, LTGO ranks #437 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LTGO compare to OBX and KURA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LTGO carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, OBX (Obsidian Therapeutics Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $913.6M) and KURA (Kura Oncology Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $912.7M). Among the 5-stock peer group, LTGO leads on earnings multiple (N/A) while ORIC leads on capital efficiency (-33.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LTGO?
▼

Per LTGO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002056611), Latigo Biotherapeutics Inc. generated $31.7M in revenue, $0 in net income, and $0 in free cash flow against $75.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $13.41 (-0.76%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 81.6% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510041
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Cash (10)Whales (3)SEC (13)Macro (6)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-7.6% Base Target
$27 Bull$12 Base$10 Bear
📬 FREE LTGO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LTGO)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (41/100 Composite)
🔍 WHY LTGO SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (32% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 81.6% FCF Margin ($25.9M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
49
Grade D$15.71-2.9% Next Q
Q2 (-2Q)
46
Grade D$15.25-0.3% Next Q
Q3 (-1Q)
44
Grade D$15.21-11.2% Next Q
Current
41
Grade D-$13.51-7.2% Hist 90D α
Trajectory: D (49) → D- (41)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LTGO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LTGO currently carries a cautious 41/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($18.62) and Max Pain ($14.19) forces dealer call-delta covering toward $27.23.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LTGO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LTGO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 41%NO 59%Trade / Inspect Odds →
CASH DIVIDEND + BUYBACK YIELD
1.8% Total Yield
0% Cash ($0.00/yr) + 1.8% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 • REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr
$10.7K
Yr 1
$11.4K
Yr 2
$12.2K
Yr 3
$13.0K
Yr 4
$13.9K
Yr 5
$14.8K
Yr 6
$15.8K
Yr 7
$16.9K
Yr 8
$18.1K
Yr 9
$19.3K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LTGO)

  • ✓Walkthrough of LTGO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
LTGO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -25.97%▼ DESCENDING CHANNEL
2026-11-03O $15.54H $15.54L $13.51C $13.51VOL 216.2K
RES: $22.39SUP: $10.81SMA50: $18.62SMA200: $18.89
$26.80$23.20$19.59$15.99$12.38RES $22.39SUP $10.81$13.512026-08-072026-08-282026-09-212026-10-122026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LTGO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LTGO Butterfly Map → + Track LTGO →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on LTGO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LTGO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LTGO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LTGO)

Health Care Rank #437 of 1015 ⚔️ OBX vs LTGO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LTGO vs. OBX, KURA, JBIO, ORIC)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Latigo Biotherapeutics Inc. (LTGO) ranks #437 by composite RQD confidence (41/100, grade D-) and #364 by equity capitalization ($924.9M). Within this direct 5-issuer industry benchmark cohort, LTGO leads on earnings valuation at N/A trailing P/E, while ORIC leads on capital efficiency and profitability with -33.4% ROIC and — gross margin. LTGO currently leads its immediate peer cohort in composite quantitative strength at 41/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
LTGO ACTIVE
Latigo Biotherapeutics Inc.
D- 41/100 — — — -3.15% $924.9M Benchmark Subject
OBX
Obsidian Therapeutics Inc.
D- 36/100 — — -35.0% -2.43% $913.6M /obx-vs-ltgo →
KURA
Kura Oncology Inc.
E 31/100 — — -35.0% -4.58% $912.7M /kura-vs-ltgo →
JBIO
Jade Biosciences Inc.
E 31/100 — — -35.0% -0.92% $894.2M /jbio-vs-ltgo →
ORIC
Oric Pharmaceuticals Inc.
E 30/100 — — -33.4% -1.84% $957.8M /oric-vs-ltgo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002056611 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Latigo Biotherapeutics Inc. (LTGO) reported GAAP revenue of $31.7M , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, LTGO closed FY2025 with $75.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $31.7M $0 — — $75.5M —

3. LTGO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LTGO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Latigo Biotherapeutics Inc. (NASDAQ: LTGO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $13.51 (-3.15% 1D, market cap $924.9M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, LTGO ranks #437 in composite RQD confidence.

How does LTGO compare to OBX and KURA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LTGO carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, OBX (Obsidian Therapeutics Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $913.6M) and KURA (Kura Oncology Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $912.7M). Among the 5-stock peer group, LTGO leads on earnings multiple (N/A) while ORIC leads on capital efficiency (-33.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LTGO?

Per LTGO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002056611), Latigo Biotherapeutics Inc. generated $31.7M in revenue, $0 in net income, and $0 in free cash flow against $75.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LTGO trading relative to its 50-day, 200-day, and 52-week technical levels?

LTGO last traded at $13.51 (-3.15% on volume of 290,072 shares), positioning the stock -27.44% below its 50-day simple moving average ($18.62) and -28.48% below its 200-day simple moving average ($18.89). Across its 52-week range of $13.50 to $25.93, LTGO sits at the 0.1% percentile with a 14-day RSI of 40.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($11.82 to $15.20).

Direct Sub-Reports: LTGO RQD Cockpit LTGO 12M Forecast LTGO Earnings & Move LTGO Dividends & DRIP LTGO Insiders & 13F LTGO Whale Options LTGO Profit Sankey LTGO News & Why
ROARABLE RATING BRIEF • RQD 41/100 (D-) ✓ SEC XBRL & RQD VERIFIED

LTGO — Latigo Biotherapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Latigo Biotherapeutics Inc. (LTGO) earns a live Roarable RQD composite score of 41/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $13.51 (-3.15% 1D, market capitalization $924.9M).

  • Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Latigo Biotherapeutics Inc. Is a NASDAQ-listed company in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. The issuer has a market capitalization of $1.0B. Reported revenue for FY 2025 is —.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Latigo Biotherapeutics Inc. (LTGO) reported $31.7M in annual revenue and $0 in GAAP net income. Operating cash flow reached $0 and free cash flow totaled $0, backed by $75.5M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 41/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $13.50 – $25.93 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), LTGO carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can LTGO sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $31.7M and free cash flow of $0, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is LTGO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

LTGO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Latigo Biotherapeutics Inc. (LTGO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LTGO Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LTGO Bull vs. Bear Conversation Board — What's Your Call at $13.51?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LTGO 🐻 33% BEARISH CONVICTION
1. Pick Your Side on LTGO:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $16.04 (+15.0%)
📌 Pinned Debate

The forensic balance sheet pillar (13/20, Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) is the strongest component of the rating and

The forensic balance sheet pillar (13/20, Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) is the strongest component of the rating and cash is reported at $69.4M.. When you look under the hood at LTGO, Fundamental Cash Engine is 10/20 with 0.0% gross margins and 0.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $25.93. My 12M target is $16.04.

SectorRotator 🐂 BULL

@SiliconVal_Bull Agree on the RQD 41/100 quality, though with 1.0 beta I'm scaling in with half-size at $13.95 and keeping dry powder in case we test $12.97.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $11.02 (-21.0%)
Spot @ $13.95

Valuation & margin reality check on LTGO at $13.95 before chasing here

Fading this rally in LTGO at $13.95. Valuation & margin reality check on LTGO at $13.95 before chasing here. With a beta of 1.0 and the stock sitting at $13.95 (52-wk range $13.50–$25.93), the easy multiple expansion is already priced in.

LIVE TAPE